Regulatory tracking is eating more time than most teams want to admit…

For small and mid-sized medtech companies, staying up-to-date is a daily drain.

But keeping up with the state-of-the-art is essential.

RAs spend at least 55 minutes or more per week just tracking updates across markets.

That does not even include the time needed to read and analyze them.

Some rely on authority newsletters when available.

Others use LinkedIn, RIM tools, or internal trackers.

But even then, someone still has to review the source, filter the noise, and figure out what is actually applicable.

In a regulatory world that keeps changing, how does your team handle regulatory updates? Let me know.

Until then, let’s get into the March regulatory updates first.

🍜 Regulation Updates

March brought a few notable updates.

China is pouring efforts into clinical innovation, while continuing to tighten implementation of the new GMP and UDI.

Let’s see what we got!

Transforming clinical innovation in medical solutions

NMPA has launched a three-year nationwide “Spring Rain Action Plan.” The goal is to speed up the path from clinical ideas to commercialized products.

In Chinese, spring rain suggests renewal and growth after winter. That fits the policy message.

This plan is not just about encouraging devices with strong clinical value.

It also aims to strengthen collaboration between hospitals, research institutes, and manufacturers.

Provincial MPAs will identify innovation projects from medical institutions. They will then screen those projects for clinical value and commercialization potential.

Regulators will help connect selected projects with medical device manufacturers for follow-up development.

So what actually changed?

In the past, device developers usually took the lead. They approach and coordinate directly with the regulators and hospitals.

Now the provincial authorities take a more proactive role. They act as a catalyst between medical institutions and manufacturers.

Projects that are successfully matched may receive incubation support and technical guidance directly from NMPA.

For Class III devices, eligible products may also enter a pre-review support channel. That means technical review can move upstream and start earlier in the R&D stage.

China is expanding UDI implementation

China will extend UDI requirements to the remaining device classes.

All Class II medical devices, all Class II IVDs, and all Class I IVDs manufactured from June 1, 2027 must carry a UDI before entering the China market.

For Class I medical devices, the requirement starts on June 1, 2029.

Manufacturers must submit product identifiers during registration and upload them to the UDI database when the requirement takes effect.

This creates another traceability obligation, similar to EUDAMED.

The notice also sets out several UDI exemptions and special implementation scenarios for certain device types.

I broke down the details in my previous post.

This matters! It affects how you align your China UDI approach with your global UDI strategy.

🍜 Guidance Documents

There are six new guidance documents in the imaging and IVD space.

Below is a summary of the intended scope, highlights, and what manufacturers should watch for.

Contrast injection equipment

The guidance covers Class II contrast injection devices used with X-ray, CT, and MRI systems. But it excludes more advanced Class III functions such as pharmacokinetic-assisted injection planning.

Registration units and joint-use validation with consumables and imaging systems are explained.

It also highlights the need to verify dose, flow accuracy, pressure control, air detection, EMC performance, MRI safety, software, cybersecurity, usability, and cleaning methods.

The guidance specifically references the core active-device and product-specific standards for these systems.

X-ray blood irradiation equipment

These are Class III devices used in hospitals or blood centers.

It irradiates bagged blood products to reduce the risk of transfusion-associated graft-versus-host disease.

It emphasizes dose distribution, dose uniformity, leakage and stray radiation, software risk, blood-bag compatibility, cleaning, transport stability, and service-life verification.

It also requires evidence based on real blood samples to show that irradiation remains safe and effective for blood components.

Reliability Evaluation of Tubing Components for X-ray Computed Tomography Equipment

This guidance is intended for CT tube assemblies, whether they are registered as standalone products or as part of a CT system.

It focuses on how manufacturers should justify the claimed service life through reliability studies.

Manufacturers shall define and explain reliability targets, statistical model, lifetime testing failure modes, and monitor performance over time.

It also points to a broad set of reliability, electrical safety, and imaging-related standards that should support the evaluation.

Dengue virus NS1 antigen test reagent

This applies to Class III IVDs that detect dengue NS1 antigen in serum, plasma, or venous whole blood.

Methods such as immunochromatography, chemiluminescence, or ELISA are used.

Manufacturers need robust analytical validation, including limit of detection, precision, inclusivity across all four dengue serotypes, cross-reactivity, interference, hook effect, and cut-off studies.

It also expects multicenter clinical studies in relevant endemic settings.

CYP2C9 and VKORC1 genotyping reagent

This is a Class III PCR-based IVD used to detect specific CYP2C9 and VKORC1 polymorphisms.

It is crucial to justify the clinical relevance of the claimed variants in the Chinese population.

Manufacturers need to submit information on analytical validation across genotype types, sample types, extraction methods, interference conditions, and cut-off settings.

It also calls for multicenter clinical studies using approved comparator products or Sanger sequencing.

Human KRAS mutation detection reagent

A Class III PCR-based test that detects KRAS mutations in FFPE colorectal cancer tissue.

Manufacturers must include clinically relevant mutations and establish a limit of detection based on both mutant allele fraction and DNA concentration.

The extraction, interference, and cross-reactivity must be validated.

Visit the CMDE website to access the full list of published guidance documents.

🍜 List of Standards

Evidence of compliance with IEC or ISO standards alone is usually not enough.

China has its own medical device standards.

Local requirements, test methods, and acceptance ranges can differ from international standards.

Knowing which requirements and standards apply to your product can save time and help you avoid hiccups during type testing.

This month, China released 26 standards and published 11 new draft standards. Below is the list of released standards.

More than 99% of manufacturers get NMPA questions on the product's technical requirements and testing in China.

Not sure which standards apply to your product in China? Let’s talk.

General Standards

• YY/T 0297-2026 - General Quality Requirements for Medical Device Clinical Trials

• YY/T 1406-2026 - Medical Device Software - Guidance on the Application of GB/T 42062 to Medical Device Software

• YY/T 2000-2026 - Medical Devices Real-World Data - Terms and Definitions

Orthopedics and musculoskeletal implants

• YY 0017-2026 - Osteosynthesis Implants - Metallic Bone Plates

• YY 0018-2026 - Osteosynthesis Implants - Metallic Bone Screws

• YY 0118-2026 - Joint Replacement Implants - Hip Prostheses - Basic Requirements

• YY 0502-2026 - Joint Replacement Implants - Knee Prostheses - Basic Requirements

Cardiovascular and neuromodulation implants

• YY/T 0492-2026 - Implantable Electrode Leads

• YY/T 2007-2026 - Cardiovascular Implants - Embolic Microspheres

Imaging and radiology

• YY/T 0479-2026 - Medical Diagnostic X-ray Tube Assemblies and X-ray Source Assemblies - Determination of the Maximum Symmetrical Radiation Field

• YY/T 1625-2026 - Particular Specifications for Mobile X-ray Computed Tomography Equipment

Dentistry

• YY/T 0517-2026 - Dentistry - Root Canal Posts

• YY/T 0825-2026 - Dentistry - External Tooth Bleaching Products

• YY/T 2009-2026 - Dentistry - In Vitro Degradation Test Method for Biodegradable Magnesium-Based Metallic Implants

Wound care and tissue repair

• YY/T 0954-2026 - Non-active Surgical Implants - Type I Collagen Implant

• YY/T 1293.3-2026 - Contacting Wound Dressings - Part 3: Sodium Carboxymethyl Cellulose Dressings

In vitro diagnostics

• YY/T 1997-2026 - Management Requirements for Biological Samples in Clinical Trials of In Vitro Diagnostic Reagents

• YY/T 1998-2026 - General Quality Requirements for Clinical Trials of In Vitro Diagnostic Reagents

• YY/T 2001-2026 - In Vitro Diagnostic Examination Systems - Requirements for the Establishment of In-house Reference Materials for Qualitative Reagents

Ultrasound and physical therapy

• YY/T 0750-2026 - Ultrasonics - Physiotherapy Systems - Requirements and Methods of Measurement for Fields in the Frequency Range 0.5 MHz to 5 MHz

Anesthesia and respiratory care

• YY/T 1438-2026 - Anaesthetic and Respiratory Equipment - Peak Expiratory Flow Meters for the Assessment of Pulmonary Function in Spontaneously Breathing Humans

Traditional Chinese medical device

• YY/T 2004.1-2026 - Traditional Chinese Medicine Devices - Skin Needle - Part 1: Percussion Type

• YY/T 2005-2026 - Traditional Chinese Medicine Devices - Acupotomy Needle

• YY/T 2006-2026 - Traditional Chinese Medicine Devices - Electric Cupping Equipment

Others

• YY/T 1953-2026 - Biological Evaluation of Nanomedical Devices - Antibacterial Performance Test

• YY/T 2008-2026 - Medical Additive Manufacturing - Polyetheretherketone Powder for Powder Bed Fusion

Visit the official NIFDC website to access the list of previously published standards. That’s it for March.

Like spring rain, regulatory change can look light at first.

But over time, it shapes the whole landscape.

The teams that notice those early shifts are usually the ones best prepared for what comes next.

Subscribe to my newsletter. Join other RA professionals to stay informed about China’s medtech regulations.

Forwarded this email? Sign up here
Follow me on LinkedIn

Disclaimer: This content is created solely in my personal interest and does not reflect the views, opinions, or policies of my employer or any other organizations I am affiliated with. Neither I nor my employer is liable for any use of this content. This newsletter does not compete with my employer’s interests. Any references to regulatory updates or guidance are based on publicly available information and are not intended to infringe upon proprietary or confidential content.